PMID- 23486907
OWN - NLM
STAT- MEDLINE
DCOM- 20160201
LR  - 20221207
IS  - 1752-8976 (Electronic)
IS  - 1470-3203 (Linking)
VI  - 16
IP  - 1
DP  - 2015 Mar
TI  - Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in 
      type 2 diabetic nephropathy.
PG  - 113-8
LID - 10.1177/1470320313481485 [doi]
AB  - INTRODUCTION: Inhibitors of the renin-angiotensin aldosterone system (RAAS) are 
      the basic drugs for treatment of diabetic nephropathy, as to some extent is 
      spironolactone. The aim of the study was to evaluate the effect of spironolactone 
      versus spironolactone plus hydrochlorothiazide in decreasing proteinuria in type 
      2 diabetic mellitus (T2DM) patients. METHODS: In a double-blind clinical trial, 
      60 T2DM patients with nephropathy randomly assigned to three equal groups were 
      enrolled. Spironolactone (50 mg/day) plus placebo, spironolactone (50 mg/day) 
      plus hydrochlorothiazide (25 mg/day), and hydrochlorothiazide (25 mg/day) plus 
      placebo were prescribed, respectively. The duration of treatment was three months 
      for all patients. Urine protein was measured at the beginning and end of the 
      study and analysis of data was performed. RESULTS: Twenty-six of the patients 
      were male, with a total mean age of 56.8 +/- 8.3 years. Mean 24-h urine protein was 
      reduced in patients in groups 1 and 2 compared to the third group (p < 0.001). 
      Serum potassium in the first group showed a significant increase of 0.26 meq/lit 
      with mean 4.64 +/- 0.28 meq/lit (p = 0.002), but it did not change in the second 
      and third groups. CONCLUSION: Our results showed that spironolactone plus 
      hydrochlorothiazide is an effective and inexpensive modality in the treatment of 
      diabetic nephropathy without increasing serum potassium.
CI  - (c) The Author(s) 2013.
FAU - Momeni, Ali
AU  - Momeni A
AD  - Shahrekord University of Medical Sciences, Iran ali.momeny@yahoo.com.
FAU - Behradmanesh, Mohammad Saeed
AU  - Behradmanesh MS
AD  - Shahrekord University of Medical Sciences, Iran.
FAU - Kheiri, Soleiman
AU  - Kheiri S
AD  - Social Health Determinants Research Center, Shahrekord University of Medical 
      Sciences, Iran.
FAU - Karami Horestani, Mohammad
AU  - Karami Horestani M
AD  - Shahrekord University of Medical Sciences, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130313
PL  - England
TA  - J Renin Angiotensin Aldosterone Syst
JT  - Journal of the renin-angiotensin-aldosterone system : JRAAS
JID - 100971636
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Blood Glucose)
RN  - 0 (Diuretics)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - 27O7W4T232 (Spironolactone)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diuretics/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hydrochlorothiazide/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Potassium/blood
MH  - Proteinuria/*drug therapy/etiology
MH  - Spironolactone/*therapeutic use
OTO - NOTNLM
OT  - Spironolactone
OT  - diabetic nephropathy
OT  - hydrochlorothiazide
EDAT- 2013/03/15 06:00
MHDA- 2016/02/02 06:00
CRDT- 2013/03/15 06:00
PHST- 2012/11/26 00:00 [received]
PHST- 2013/01/12 00:00 [accepted]
PHST- 2013/03/15 06:00 [entrez]
PHST- 2013/03/15 06:00 [pubmed]
PHST- 2016/02/02 06:00 [medline]
AID - 1470320313481485 [pii]
AID - 10.1177/1470320313481485 [doi]
PST - ppublish
SO  - J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):113-8. doi: 
      10.1177/1470320313481485. Epub 2013 Mar 13.